Osseointegration of cementless implants with different bisphosphonate regimens

Clinical Orthopaedics and Related Research

Volumn 447, Issue , 2006, Pages 195-200

  Eberhardt, Christian ^a   Stumpf, Ulla ^a   Brankamp, Jochen ^a   Schwarz, Markus ^b   Kurth, Andreas H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CEMENT; HYDROXYAPATITE; IBANDRONIC ACID; NITROGEN; SODIUM CHLORIDE; TITANIUM; BONE CEMENT; BONE DENSITY CONSERVATION AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MINERALIZATION; BONE REGENERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR; METAL IMPLANTATION; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; ANALYSIS OF VARIANCE; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; INTRALESIONAL DRUG ADMINISTRATION; NEEDLE BIOPSY; PROSTHESES AND ORTHOSES; RADIOGRAPHY; RANDOMIZATION; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; BONE CEMENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMUR; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; OSSEOINTEGRATION; PROSTHESES AND IMPLANTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TITANIUM;

EID: 33746083289     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/01.blo.0000201170.57141.66     Document Type: Article

References (44)

1. An YH. Methods of Evaluation in Orthopaedic Animal Research. In: An YH, Friedman RJ, eds. Animal Models in Orthopaedic Research. Boca Raton, FL: CRC Press; 1999:92-93.
2. Astrand J, Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop Scand. 2002;73:24-30.
3. Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res. 2004;22:244-249.
4. Bauss F, Lalla S, Endele R, Hothorn LA. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002;29:2200-2208.
5. Bauss F, Scimmer RC. Effect of daily and intermittent use of ibandronate on bone mass and bone turn over in postmenopausal osteoporosis. Clin Ther. 2003;25:19-34.
6. Bauss F, Wagner M, Hothorn LH. The total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol. 2002;29:990-998.
7. Berruti A, Dogliotti L, Tucci M, Tarabuzzi R, Guercio S, Torta M, Tampellini M, Dovio A, Poggio M, Scarpa RM, Angeli A. Metabolic effects of a single-dose pamidronate administration in prostate cancer patients with bone metastases. Int J Biol Markers. 2002;17:244-252.
8. Bhandari M, Bajammal S, Guyatt GH, Griffith L, Busse JW, Schunemann H, Einhorn TA. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. J Bone Joint Surg. 2005;87:293-301.
9. Bragdon CR, Doherty AM, Jasty M, Rubash HE, Harris WH. Effect of oral alendronate on net bone ingrowth into canine cementless total hips. J Arthroplasty. 2005;20:258-263.
10. Branemark PI, Hansson BO, Adell R, Breine U, Lindstrom J, Hallen O, Ohman A. Osseointegrated implants in the treatment of edentulous jaw: experience from a 10-year period. Scand J Plast Reconstr Surg Suppl. 1977;16:1-132.
11. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittent on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249.
12. Denissen H, van Beek E, van den Bos T, de Blieck J, Klein C, van den Hooff A. Degradable bisphosphonate-alkaline phosphatase-complexed hydroxyapatite implants in vitro. J Bone Miner Res. 1997;12:290-297.
13. Dörre E. Hydroxyapatite ceramic coatings for anchoring components of hip joint prostheses. Biomed Tech. 1989;34:46-52.
14. Fogelman I. Diphosphonate bone scanning agents-current concepts. Eur J Nucl Med. 1982;7:506-509.
15. Friedman RJ, An YH, Ming J, Draughn RA, Bauer TW. Influence of biomaterial surface texture on bone ingrowth in the rabbit femur. J Orthop Res. 1996;14:455-464.
16. Hartwig CH, Esenwein SA, Pfund A, Kusswetter Dagger W, Herr G. Improved osseointegration of titanium implants of different surface characteristics by the use of bone morphogenetic protein (BMP-3): an animal study performed at the metaphyseal bone bed in dogs. [in German] Z Orthop Ihre Grenzgeb. 2003;141:705-711.
17. Hennigs T, Arabmotlagh M, Schwarz A, Zichner L. Dose-dependent prevention of early periprosthetic bone loss by alendronate. [in German] Z Orthop Ihre Grenzgeb. 2002;140:42-47.
18. Hunziker J, Wronski TJ, Miller SC. Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone. J Dent Res. 2000;79:1431-1438.
19. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25:4105-4115.
20. Jaffe WL, Scott DF. Total hip replacement with hydroxyapatite-coated prostheses. J Bone Joint Surg. 1996;78:1918-1934.
21. Kienapfel H, Sprey C, Wilke A, Griss P. Implant fixation by bone ingrowth. J Arthroplasty. 1999;14:355-368.
22. Kurth AH, Eberhardt C, Müller S, Steinacker M, Schwarz M, Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone. 2005;37:204-210.
23. Lind M, Overgaard S, Ongpipattanakul B, Nguyen T, Bunger C, Soballe K. Transforming growth factor-beta 1 stimulates bone ongrowth to weight-loaded tricalcium phosphate coated implants: an experimental study in dogs. J Bone Joint Surg. 1996;78:377-382.
24. Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol. 1999;70:151-158.
25. Monier-Faugere MC, Geng Z, Paschalis E, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res. 1999;14:1768-1778.
26. Okamoto Y. Accumulation of technetium-99m methylene diphosphonate: conditions affecting adsorption to hydroxyapatite. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995;80:115-119.
27. Papapoulos SE. Ibandronate: a potent new bisphosphonate, in the management of postmenopausal osteoporosis. Int J Clin Pract. 2003;57:417-422.
28. Pataki A, Müller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec. 1997;249:458-468.
29. Piliar SM, Lee JM, Maniatopoulos C. Observations of the effect of movement on bone ingrowth into porous-surfaced implants. Clin Orthop Relat Res. 1986;208:108-113.
30. Rahmy AI, Tonino AJ, Tan WD. Quantitative analysis of technetium-99m-methylene diphosphonate uptake in unilateral hydroxyapatite- coated total hip prostheses: first year of follow-up. J Nucl Med. 1994;35:1788-1791.
31. Ralston SH, Alzaid AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcaemia. Q J Med. 1988;68:825-834.
32. Reid IR, Brown JP, Burckhardt P, Meunier PJ. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
33. Riley EH, Lane JM, Urist MR, Lyons KM, Lieberman JR. Bone morphogenetic protein-2: biology and applications. Clin Orthop Relat Res. 1996;324:39-46.
34. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97-106.
35. Schimmer RC, Bauss F. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther. 2003;25:19-34.
36. Skripitz R, Andreassen TT, Aspenberg P. Parathyroid hormone (1-34) increases the density of rat cancellous bone in a bone chamber: a dose-responsive study. J Bone Joint Surg. 2000;82:138-141.
37. Soininvaara TA, Jurvelin JS, Miettinen HJ, Suomalainen OT, Alhava EM, Kroger PJ. Effect of alendronate on periprosthetic bone loss after knee arthroplasty: a one-year, randomized, controlled trial of 19 patients. Calcif Tissue Int. 2002;71:472-477.
38. Stutzer A, Fleisch H, Trechsel U. Short- and long-term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomized rats. Calcif Tissue Int. 1988;43:294-299.
39. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schoter KH. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med. 1997;103:298-307.
40. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P. Dose-response in the treatment of hypercalcaemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol. 1988;6:762-768.
41. Von Knoch M, Wedemeyer C, Pingsmann A, von Knoch F, Hilken G, Sprecher C, Henschke F, Barden B, Loer F. The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials. 2005;26:1803-1808.
42. Wang X, Shanbhag AS, Rubash HE, Agrawal CM. Short-term effects of bisphosphonates on the biomechanical properties of canine bone. J Biomed Mater Res. 1999;44:456-460.
43. Weinans H, Huiskes R, Grootenboer HJ. Quantitative analysis of bone reactions to relative motions at implant-bone interfaces. J Biomech. 1993;26:1271-1281.
44. Wilke A, Orth J, Lomb M, Fuhrmann R, Kienapfel H, Griss P, Franke RP. Biocompatibility analysis of different biomaterials in human bone marrow cell cultures. J Biomed Mater Res. 1998;40:301-306.